Daily Cosmetic Research Analysis
Analyzed 13 papers and selected 3 impactful papers.
Summary
Today’s top cosmetic-related studies span clinical, preclinical, and health-services research. A randomized split-face trial shows a PDLLA+HA filler is non-inferior to PLLA for nasolabial fold correction. A preclinical pig study identifies micro-focused ultrasound immediately before PLLA as the optimal sequence for enhanced dermal remodeling, while a rapid review quantifies NHS burdens from elective surgical tourism, including cosmetic procedures.
Research Themes
- Biostimulatory fillers and injectable materials
- Energy-based device and filler combination sequencing
- Cosmetic surgery tourism and health system burden
Selected Articles
1. A Split Face Study Comparing the Effect of a PDLLA Based Product and PLLA on the Nasolabial Fold (NLF).
In a multicenter, randomized, evaluator-blinded split-face study (n=33), a PDLLA + non-cross-linked hyaluronic acid product achieved nasolabial fold improvements comparable to PLLA across all time points based on WSRS. Both treatments significantly improved wrinkle severity from baseline (p<0.001), with similar safety profiles reported. Longer follow-up is needed to clarify durability and rare adverse events.
Impact: This is a rigorous head-to-head, randomized split-face comparison showing non-inferiority of a new PDLLA-based product to an established PLLA standard for NLF correction, directly informing injectable selection.
Clinical Implications: Clinicians can consider PDLLA+HA as an alternative to PLLA for nasolabial fold correction with comparable short-term efficacy, using split-face insights to guide product selection and patient counseling about benefits and unknown long-term safety.
Key Findings
- Both PDLLA-based and PLLA injections significantly improved nasolabial fold severity versus baseline at all measured time points (p<0.001).
- Improvements were comparable between PDLLA+HA and PLLA throughout the 24-week observation window, supporting non-inferiority.
- Design utilized multicenter, randomized, evaluator-blinded split-face methodology with three sessions at 4-week intervals and WSRS assessments.
Methodological Strengths
- Randomized, evaluator-blinded split-face design reduces inter-subject variability and assessment bias.
- Standardized imaging and validated WSRS outcomes across predefined time points.
Limitations
- Modest sample size (n=33) and follow-up limited to 24 weeks; long-term durability and rare adverse events remain unassessed.
- Safety outcomes are summarized but detailed adverse event rates are not specified in the abstract.
Future Directions: Larger, longer-term randomized trials with standardized safety monitoring (e.g., nodule/granuloma rates) and patient-reported outcomes are needed to confirm durability and safety across facial indications.
BACKGROUND: Injectable Poly-L-lactic acid (PLLA) is effective in restoring mid-face volume and is widely used treating the nasolabial fold (NLF). This study aimed to compare the safety and efficacy of a novel PDLLA based product (PDLLA + non-cross-linked HA; Poly-D, L-lactic acid + hyaluronic acid) with that of a commonly used PLLA for NLF correction. METHODS: In this multi-center, randomized, split-face, evaluator-blinded study, 33 subjects received injections of the PDLLA based product on one NLF and PLLA injection on the other (three injections total, administered at 4-week intervals). Wrinkle severity was assessed using standardi
2. Enhancing the Efficacy of Poly-l-Lactic Acid Injections With Micro-Focused Ultrasound: An Evaluation of Combined Treatment and Optimal Sequence.
In a controlled preclinical pig model, MFU immediately before PLLA produced the greatest dermal remodeling: +35.2% dermal thickness and a type III/I collagen ratio of 0.92, outperforming either modality alone. MFU did not hasten PLLA degradation or increase inflammation, supporting the safety and mechanistic rationale for this sequence.
Impact: This study addresses a practical gap by defining an optimal sequence for combining an energy-based device with a biostimulatory filler, supported by multi-modal histologic and ultrastructural evidence.
Clinical Implications: Clinicians may consider MFU immediately before PLLA to maximize dermal remodeling while maintaining safety; human trials should validate clinical outcomes, parameters, and patient-reported benefits before routine adoption.
Key Findings
- PLLA alone increased dermal thickness by 23.7% and raised the type III/I collagen ratio to 0.79 ± 0.06 (p<0.01).
- MFU alone predominantly enhanced type I collagen (ratio 0.39 ± 0.04) and improved fiber alignment.
- MFU immediately before PLLA yielded the best remodeling: +35.2% dermal thickness and type III/I collagen ratio 0.92 ± 0.05 (both p<0.01), with denser elastin and organized fat septa.
- MFU did not accelerate PLLA microsphere degradation or increase inflammatory infiltration versus PLLA alone (p>0.05).
Methodological Strengths
- Within-animal, multi-zone controlled design minimizing biological variability.
- Comprehensive histology (Masson's, Sirius Red, VVG, H&E), SEM, and quantitative image analyses with 180-day follow-up.
Limitations
- Small number of animals (n=3) limits generalizability and statistical power.
- Preclinical model lacks direct human clinical outcomes and safety data.
Future Directions: Conduct human randomized trials to test MFU→PLLA sequencing versus alternatives, optimize energy/filler parameters, and correlate histology with clinical scales and patient-reported outcomes.
INTRODUCTION: Poly-l-lactic acid (PLLA) and micro-focused ultrasound (MFU) are widely used for skin rejuvenation, each promoting collagen remodeling through distinct mechanisms. While combined use is common in practice, the optimal treatment sequence and safety profile remain unclear. This study aimed to evaluate the synergistic effects and ideal sequencing of PLLA and MFU in a preclinical model to guide clinical protocols. METHODS: Three Bama miniature pigs were subjected to six treatment conditions on demarcated abdominal skin zones: (a) PLLA alone, (b) MFU alone, (c) MFU immediately before PLLA, (d) MFU 1 month before PLLA, (e) MFU 1 month after PLLA, and (f) untreated control. Löviselle PLLA was injected subcutaneously, while MFU was administered using the MFUS Pro system. Skin biopsies were collected at day 180. Histological (Masson's trichrome, Sirius Red, Verhoeff-Van Gieson, H&E), SEM, and quantitative image analyses were performed to assess dermal thickness, collagen subtype distribution, elastin regeneration, fat septa organization, and PLLA microsphere stability. RESULTS: PLLA alone increased dermal thickness by 23.7% and raised the type III/I collagen ratio to 0.79 ± 0.06 (p < 0.01). MFU alone mainly enhanced type I collagen (ratio: 0.39 ± 0.04) and improved fiber alignment. The combined treatment with MFU immediately before PLLA achieved the best outcomes: dermal thickness increased by 35.2%, and the type III/I collagen ratio reached 0.92 ± 0.05 (both p < 0.01). This group also showed denser elastin fibers, well-structured fat septa, and the most compact collagen morphology under SEM. MFU did not accelerate PLLA degradation or increase inflammation, with no significant difference in microsphere size or inflammatory infiltration compared to PLLA alone (p > 0.05). CONCLUSION: Sequential application of MFU immediately before PLLA enhances dermal remodeling more effectively than either treatment alone, without compromising PLLA microsphere stability. These findings support the clinical potential and safety of this combinatory approach, offering evidence-based guidance for optimizing skin rejuvenation protocols.
3. Complications and costs to the UK National Health Service due to outward medical tourism for elective surgery: a rapid review.
This rapid review synthesized 35 case series/reports and two surgeon surveys, identifying 655 patients treated within the NHS for complications after elective surgery abroad (385 bariatric, 265 cosmetic, 5 ophthalmic). Cosmetic tourism complications most commonly included infection and wound dehiscence; per-patient NHS costs ranged from £1,058 to £19,549 (2024 prices). The review highlights major data gaps and calls for systematic surveillance.
Impact: By quantifying complications and costs linked to outward surgical tourism, including cosmetic procedures, this review informs risk counseling, commissioning, and policy for post-travel care within the NHS.
Clinical Implications: Clinicians should proactively counsel prospective medical tourists on complication risks and potential NHS resource implications. Health systems should implement standardized reporting/coding to track cases, costs, and outcomes, and develop post-travel care pathways.
Key Findings
- Across 35 case series/reports and 2 surveys, 655 patients were treated within the NHS for complications after elective surgery abroad (2006–2024): 385 bariatric, 265 cosmetic, 5 ophthalmic.
- Most patients were women (90%), mean age 38 years; Turkey was the most common destination (61%).
- For cosmetic surgery tourism, infection and wound dehiscence were most frequently reported complications; some required prolonged hospitalization and multiple reoperations.
- Per-patient NHS costs ranged from £1,058 to £19,549 (2024 prices); no studies reported benefits of outward medical tourism.
Methodological Strengths
- Comprehensive search including medical and grey literature with JBI appraisal and GRADE approach for cost certainty.
- Clear inclusion/exclusion criteria and focused outcomes on costs and complications with narrative synthesis.
Limitations
- Evidence base dominated by case series and case reports with heterogeneity and incomplete reporting; very low certainty for cost estimates.
- Rapid review design without meta-analysis; potential publication and selection biases.
Future Directions: Establish standardized national surveillance and registries for surgical tourism, capturing procedures, complications, costs, and outcomes; conduct prospective studies and evaluate pre/post-travel counseling interventions.
OBJECTIVES: Outward medical tourism is when people seek medical treatment in a different country to the one they live in. We aimed to identify all studies that describe the impact on the UK National Health Service (NHS) of patients who require treatment due to outward medical tourism for elective surgery and report on complications, costs and benefits. DESIGN: A rapid literature review. Medical and grey literature databases were searched, limited to literature published between 2012 and 2024. SELECTION CRITERIA: Studies published in the English language, conducted in any NHS setting, describing complications, costs or benefits due to outward medical tourism for elective surgery were included. We excluded emergency and semi-urgent surgery, dental and transplant surgery, cancer treatment and fertility treatment. OUTCOME MEASURES: Primary outcomes were costs and savings to the NHS. Secondary outcomes were type and frequency, demographics, procedures, complications, treatment, follow-up care and use of NHS resources. Results were summarised narratively. Study quality was assessed using JBI critical appraisal tools and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used for certainty of evidence for costs. RESULTS: Some 35 case series and case reports and two surveys of NHS plastic surgeons were identified. Case studies described 655 patients treated in specific NHS hospitals between 2006 and 2024 for postoperative complications due to metabolic/bariatric surgery (n=385), cosmetic (n=265) and ophthalmic (n=5) surgery tourism. No cases relating to other surgical specialities were identified in the literature. Most patients were women (90%), with an average age of 38 (range 14-69) years. The most common destination for surgery was Turkey (61%). Complications were not well described for metabolic/bariatric surgery tourism; but for cosmetic surgery tourism, infection and wound dehiscence were most commonly reported. There was evidence that some patients needed complex treatment involving long hospital stays and multiple surgical interventions. Very low certainty evidence indicated that costs to the NHS from outward medical tourism for elective surgery ranged from £1058 to £19 549 per patient in 2024 prices. We found no studies that reported on the benefits of outward medical tourism. CONCLUSIONS: A systematic approach is needed to collecting information on the number of people who travel abroad for elective surgery and the frequency and impact on the UK NHS of treating complications. Without these data, we cannot fully understand the risk of seeking surgery abroad.